Blake Borgeson, Director at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 50,000 shares at $4.84 ($242K) on 2026-10-06, disclosed to the SEC on 2026-10-07.
Scheduled sale ($242k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RXRX | SELL | 2026-07-09 | $159K | — | Filing → |
| RXRX | SELL | 2026-06-04 | $110K | — | Filing → |
| RXRX | SELL | 2026-05-07 | $106K | — | Filing → |